Bioabsorbable Stents Market Outlook:
Bioabsorbable Stents Market size was USD 1.3 billion in 2024 and is projected to reach USD 6.8 billion by the end of 2037, registering at a CAGR of 17.2% during the forecast period, i.e., 2025-2037. In 2025, the industry size of bioabsorbable stents is estimated at USD 1.7 billion.
The worldwide patient pool in the market is readily increasing, owing to a rise in the prevalence of cardiovascular disorders, with ischemic heart disease affecting an estimated 198 million people globally. Besides, coronary interventions utilizing bioabsorbable stents are also increasing at an approximate 8.5% yearly rate, which is attributed to boosted diagnostic rates and aging populations, especially in emerging economies. Besides, the supply chain aspect for the market includes customized polymer, along with metal alloy raw materials, with 65% to 75% of high-purity and medical-grade polymers sourced from Japan, Germany, and the U.S. The production of active pharmaceutical ingredients (APIs) for drug-eluting bioabsorbable stents is concentrated in administrative markets, based on strict good manufacturing practice (GMP) policies.
Furthermore, the producer price index (PPI) has surged by 4.4% year-over-year (YoY) for the market between 2023 and 2024, which has effectively reflected an increase in raw materials and research and development expenses. Likewise, the consumer price index (CPI) for these devices has also increased by 3.9% yearly, which is readily influenced by hospital procurement and delays in the supply chain. Besides, international trade data has indicated that the EU and the U.S. jointly account for almost 78% of bioabsorbable stent exports, while Asia-Pacific dominates imports, owing to localized assembly, thereby suitable for uplifting the market across different nations.
Bioabsorbable Stents Sector: Growth Drivers and Challenges
Growth Drivers
- Technological innovation and FDA acceptances: The aspect of advancement is readily accelerating the market adoption internationally. For instance, as per the 2024 FDA report, the organization has approved ultra-thin PLLA stents of 85µm, which tend to improve deliverability in complicated lesions. Besides, the EU has made an investment of €155 million for magnesium-specific stents through Horizon Europe. At present, the tactical priority remains in terms of R&D funding in rapid absorbable materials, along with smart stents, thus denoting a positive impact on the market.
- Sudden transition towards ambulatory and outpatient care: The aspect of the ongoing shift towards the integration of care facilities is an effective factor for the market. For instance, an estimated 67.5% of the U.S. PCIs currently take place in outpatient settings, which tends to diminish expenses by almost USD 8,200 per procedure. Besides, cardiac centers in Germany have reported that approximately 45% of short recovery times are associated with bioabsorbable stents. However, manufacturers need to redesign stents to ensure ASC compatibility and collaborate with outpatient clinics to accelerate the adoption.
Manufacturer Strategies Shaping Bioabsorbable Stents Market Expansion
Leading manufacturers in the market are implementing regulatory advancements, strategic partnerships, and product innovation to expand their respective market positions. For instance, Abbott Laboratories has enhanced its U.S. market share by almost 18.5% as of 2023 by implementing next-generation Absorb GT1 stents and further optimizing complicated lesions. Meanwhile, Boston Scientific went into a partnership with more than 45 hospitals in the U.S., which bolstered its revenue by USD 225 million through bundled procurement deals, thereby creating an optimistic outlook for the overall market.
Revenue Potential for Bioabsorbable Stent Manufacturers (2023-2025)
|
Company |
Strategy |
Revenue Impact (2023) |
Market Share Growth |
|---|---|---|---|
|
Abbott Laboratories |
Ultra-thin PLLA stent (Absorb GT1) |
+USD 325 million |
+18.5% (U.S.) |
|
Boston Scientific |
Hospital procurement partnerships |
+USD 225 million |
+9.8% (Global) |
|
Biotronik |
Magnesium stent EU expansion |
+€155 million |
+12.6% (Germany) |
|
Medtronic |
Outpatient-optimized stent launches |
+USD 182 million |
+7.7% (ASC sector) |
Feasible Expansion Models Shaping the Future of the Bioabsorbable Stents Market
Manufacturers in the market are readily adopting regulatory-driven market accessibility, value-based partnerships, and localized production procedures to ensure global expansion. For instance, suppliers in India are effectively collaborating with local hospitals under the PLI scheme, which has diminished stent expenses by almost 28% and enhanced revenue by 12.8% between 2022 and 2024. Likewise, Germany’s G-BA has incentivized bundled payments for PCI procedures, which, in turn, bolstered the bioabsorbable stents adoption by 17% as of 2023, thus suitable for propelling the market across different nations.
Feasibility Models for Market Expansion
|
Model |
Region |
Revenue Impact |
Adoption Growth |
|---|---|---|---|
|
Localized Manufacturing |
India |
+12.8% (2022-2024) |
28% cost reduction |
|
Bundled Payment Schemes |
Germany |
+€225 million (2023) |
17% PCI adoption |
|
Medicare Coverage |
USA |
+USD 485 million (2023) |
25% revenue surge |
Challenges
- Reimbursement and pricing gaps: The bioabsorbable stents market is facing significant obstacles, owing to reimbursement and pricing risks. For instance, Medicaid, in the U.S., covers only 36.5% of eligible patients, since the expenses of these stents is USD 2,550 per unit, which is more than 2.5 times conventional drug-eluting stents (DES). Europe-based markets, such as Germany, have effectively imposed stringent price caps and have forced manufacturers to reduce prices by almost 22% as of 2023. To this, payers have argued that long-lasting cost savings are not completely quantified, thus resulting in strict coverage policies.
- Delays in administrative trends: The presence of strict regulatory demands has slowed down entries into the bioabsorbable stents market globally. In this regard, a backlog in the FDA has resulted in postponing more than 2 major stent launches as of 2024. Therefore, these delays effectively increase the delay in revenue generation, along with R&D expenses. However, to overcome this challenge, organizations, such as Abbott, have engaged in conducting early regulatory consultations to streamline product and service approvals.
Bioabsorbable Stents Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
17.2% |
|
Base Year Market Size (2024) |
USD 1.3 billion |
|
Forecast Year Market Size (2037) |
USD 6.8 billion |
|
Regional Scope |
|
Bioabsorbable Stents Market Segmentation:
Application Segment Analysis
The coronary artery disease (CAD) effectively dominated the bioabsorbable stents market with an expected revenue share of 75.8% by the end of 2037. The segment’s growth is effectively fueled by the superior clinical outcomes of bioresorbable scaffolds, along with an increase in the prevalence of CAD. Besides, the World Health Organization (WHO) has estimated that approximately 18.5 million CAD deaths take place yearly, which has increased the market demand. The EU and the U.S. effectively lead the adoption, with Medicare covering almost 50% of CAD-based bioabsorbable stent procedures, thereby suitable for the segment’s growth.
End user Segment Analysis
The hospitals segment is expected to hold a market share of 67.5% in the bioabsorbable stents market by the end of the forecast period due to established reimbursement pathways and conducting complicated PCI procedures. As per the CDC report, more than 1.4 million coronary interventions are performed every year in the U.S.-based hospitals, and as stated in the CMS report, these infrastructures readily benefit from Medicare’s coverage of 85% of inpatient bioabsorbable stent procedures in comparison to only 48% in outpatient environments. Besides, the transition toward value-specific care is escalating the adoption, since hospitals have identified that bioabsorbable stents tend to reduce 20% of readmissions within a month, thus denoting a positive impact on the market.
Our in-depth analysis of the bioabsorbable stents market includes the following segments:
|
Segment |
Subsegment |
|
Application |
|
|
End user |
|
|
Material |
|
|
Absorption Rate |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Bioabsorbable Stents Market - Regional Synopsis
North America Market Insights
North America effectively dominates the bioabsorbable stents market with a projected 41.8% revenue share by the end of 2037, which includes a 15.7% growth rate. The region’s leadership originates from innovative healthcare infrastructure, favorable reimbursement policies, and a surge in PCI procedure volumes. Besides, Medicare covers 85% of inpatient bioabsorbable stent procedures in the U.S., and the single-payer system in Canada ensures broad accessibility. Meanwhile, the FDA’s rapid acceptance pathway, catering to 13 to 19 months, also accelerates the innovation, with over 4 next-generation stents anticipated to launch by the end of 2026, thereby suitable for uplifting the market.
The bioabsorbable stents market in the U.S. is significantly gaining traction and accounts for 92% of the region’s market share. The market’s growth in the country is fueled by Medicare’s USD 855 million yearly spending on these devices. Besides, the CDC has stated that an estimated 800,250 yearly PCI procedures take place with the utilization of these devices, based on which adoption rates have doubled since 2020. The shift towards outpatient settings, constituting 57% of procedures in 2025, and the FDA’s Breakthrough Device designation for more than 2 latest stent technologies as of 2024 are other key trends positively impacting the market in the country.
The bioabsorbable stents market in Canada is steadily growing with a 15% growth rate. The market’s upliftment is highly attributed to the existence of provincial health plans that cover 80% of stent expenses. In addition, Ontario has successfully funded approximately 200,250 procedures yearly, while Atlantic provinces cover up to 45%. Besides, the 2023 Canada-based Cardiovascular Society guidelines have readily prioritized bioabsorbable stents for young patients, which also drives the market demand by 28%. Therefore, all these factors are responsible for boosting the market growth in the country.
Europe Market Insights
Europe in the bioabsorbable stents market is projected to account for 30.5% of the revenue share by the end of the forecast period. The market’s upliftment in the region is effectively fueled by EU-based standardization of reimbursement policies, an increase in PCI volumes, and a surge in the aging population. Besides these factors, Germany is leading the market adoption with €4.3 billion in yearly spending, while the UK and France have readily prioritized affordability and mandated outcomes-specific pricing for stent procurement. The EU Medical Device Regulation (MDR) has escalated acceptances and reduced timelines by 32% since 2021, with over 10 next-generation stents greenlit as of 2023.
The bioabsorbable stents market in Germany is expected to capture 38% of the region’s revenue during the forecast timeline, owing to the existence of the €4.3 billion yearly market, along with 600,008 PCI procedures. Besides, the G-BA’s advanced fund provision has allocated €350 million per year for next-generation stents, and meanwhile, bundled payments cover almost 94% of procedures. Moreover, the outpatient adoption has increased with a growth rate of 21%, which is highly supported by AI-powered stent designs that are funded by Horizon Europe, thereby suitable for uplifting the market in the country.
The bioabsorbable stents market in the UK is gaining increased exposure by grabbing 22.5% of the region’s market share, of which £1.3 billion has been allocated for NHS spending as of 2023. NICE guidelines have prioritized bioabsorbable stents for patients under 65 years of age, which readily drives the yearly demand growth by 15.8%. Besides, the aspect of post-Brexit has resulted in the MHRA approving more than 8 latest stents in 2024, which has escalated the overall accessibility. Furthermore, the £220 million AI-based stent initiative effectively aims to diminish restenosis rates by almost 26% by 2030, thus creating an optimistic outlook for the market.
Key Bioabsorbable Stents Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The international bioabsorbable stents market is extremely fusion-based, with Abbott, Boston Scientific, and Medtronic jointly controlling almost 58% of the overall market. These key players have readily invested in polymer innovations, along with AI-powered designs. Meanwhile, regional players such as Lepu Medical and Meril Life Sciences effectively compete through cost-effective solutions. Besides, Germany’s Biotronik is leading in magnesium stents and has captured almost 12% of the market share. Hospital procurement deals as well as emerging market localization are two essential trends that are responsible for positively uplifting the market globally.
Here is a list of key players operating in the global market:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|---|---|---|---|
|
Abbott Laboratories |
U.S. |
22.8% |
Leading developer of Absorb GT1 bioresorbable scaffold |
|
Boston Scientific |
U.S. |
18.6% |
Focus on Synergy Megatron bioabsorbable stents |
|
Medtronic |
U.S. |
15.9% |
Resolute Onyx bioabsorbable polymer technology |
|
Biotronik |
Germany |
10.4% |
Magnesium-based absorbable stents (Magmaris) |
|
Elixir Medical |
U.S. |
8.8% |
DESyne BD novolimus-eluting bioabsorbable stent |
|
REVA Medical |
U.S. |
xx% |
Fantom sirolimus-eluting bioresorbable scaffold |
|
Terumo Corporation |
U.S./EU |
xx% |
Ultimaster bioabsorbable PLLA stents |
|
Meril Life Sciences |
India |
xx% |
MeRes100 bioresorbable stent for emerging markets |
|
Lepu Medical (China) |
China |
xx% |
Bioabsorbable PLLA stents for APAC markets |
|
MicroPort Scientific |
China |
xx% |
Firesorb bioresorbable sirolimus-eluting stent |
|
SMT (Sahajanand Medical) |
India |
xx% |
BioMime sirolimus-eluting bioabsorbable stent |
|
Cardionovum |
Germany |
xx% |
PLLA-based absorbable stents |
|
Balton (Poland) |
Poland |
xx% |
Bioabsorbable magnesium stents |
|
Alvimedica (Turkey) |
Turkey |
xx% |
Bioabsorbable coronary scaffolds |
|
OrbusNeich (Hong Kong) |
Hong Kong |
xx% |
COMBO dual-therapy bioabsorbable stent |
Below are the areas covered for each company in the bioabsorbable stents market:
Recent Developments
- In March 2024, Boston Scientific unveiled the SYNERGY Megatron Bioabsorbable Stent in Europe after gaining the CE Mark, with a proprietary sirolimus-eluting polymer that can reduce inflammation risks.
- In January 2024, Abbott Laboratories received the FDA acceptance for its cutting-edge Absorb GTX bioresorbable stent, which features 25.5% rapid absorption within two years and enhances the radial strength.
Author Credits: Radhika Pawar
- Report ID: 3612
- Published Date: Jun 26, 2025
- Report Format: PDF, PPT
